| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 31 | 2022 | 956 | 5.070 |
Why?
|
| Prostatic Neoplasms | 13 | 2022 | 262 | 2.800 |
Why?
|
| Tamoxifen | 9 | 2016 | 56 | 2.540 |
Why?
|
| Cancer Survivors | 4 | 2022 | 91 | 2.250 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2024 | 247 | 2.050 |
Why?
|
| Aromatase Inhibitors | 6 | 2016 | 33 | 2.020 |
Why?
|
| Survivors | 10 | 2022 | 158 | 1.850 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2017 | 64 | 1.650 |
Why?
|
| Humans | 78 | 2024 | 17707 | 1.450 |
Why?
|
| Aged | 54 | 2024 | 6150 | 1.430 |
Why?
|
| Neoplasms | 3 | 2023 | 442 | 1.360 |
Why?
|
| Androgen Antagonists | 5 | 2017 | 17 | 1.350 |
Why?
|
| Middle Aged | 55 | 2024 | 7976 | 1.290 |
Why?
|
| Cardiovascular Diseases | 6 | 2017 | 596 | 1.160 |
Why?
|
| Female | 46 | 2024 | 12729 | 1.080 |
Why?
|
| Depressive Disorder | 2 | 2022 | 220 | 1.030 |
Why?
|
| Proportional Hazards Models | 13 | 2021 | 710 | 1.020 |
Why?
|
| California | 21 | 2023 | 2327 | 1.000 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 29 | 0.910 |
Why?
|
| CA-125 Antigen | 2 | 2020 | 6 | 0.860 |
Why?
|
| Health Maintenance Organizations | 4 | 2017 | 414 | 0.840 |
Why?
|
| Membrane Proteins | 2 | 2020 | 39 | 0.840 |
Why?
|
| Ovarian Neoplasms | 2 | 2020 | 50 | 0.810 |
Why?
|
| Adult | 31 | 2022 | 7658 | 0.800 |
Why?
|
| Aged, 80 and over | 20 | 2021 | 1927 | 0.790 |
Why?
|
| Neoplasm Staging | 13 | 2016 | 331 | 0.780 |
Why?
|
| Paroxetine | 2 | 2015 | 23 | 0.740 |
Why?
|
| Male | 38 | 2024 | 10094 | 0.720 |
Why?
|
| Risk Factors | 19 | 2021 | 3367 | 0.710 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 280 | 0.690 |
Why?
|
| Retrospective Studies | 13 | 2023 | 2471 | 0.690 |
Why?
|
| Depression | 3 | 2022 | 504 | 0.680 |
Why?
|
| Cohort Studies | 20 | 2022 | 2589 | 0.660 |
Why?
|
| Insurance, Health | 1 | 2021 | 175 | 0.650 |
Why?
|
| Obesity | 4 | 2021 | 841 | 0.640 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 203 | 0.600 |
Why?
|
| Endometrial Neoplasms | 2 | 2015 | 35 | 0.600 |
Why?
|
| Patient Compliance | 3 | 2020 | 299 | 0.590 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 32 | 0.560 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 3 | 0.550 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 2 | 0.550 |
Why?
|
| Prognosis | 11 | 2022 | 613 | 0.510 |
Why?
|
| Sigmoidoscopy | 2 | 2007 | 65 | 0.510 |
Why?
|
| Algorithms | 4 | 2020 | 237 | 0.500 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2015 | 28 | 0.500 |
Why?
|
| Pathology Department, Hospital | 1 | 2015 | 3 | 0.480 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2017 | 14 | 0.480 |
Why?
|
| Diphosphonates | 1 | 2016 | 65 | 0.480 |
Why?
|
| Overweight | 2 | 2021 | 270 | 0.480 |
Why?
|
| Medication Adherence | 2 | 2017 | 245 | 0.470 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2015 | 41 | 0.470 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2016 | 18 | 0.460 |
Why?
|
| Biomarkers, Tumor | 4 | 2020 | 144 | 0.440 |
Why?
|
| Research Design | 1 | 2015 | 372 | 0.410 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 58 | 0.410 |
Why?
|
| Arsenic | 4 | 2007 | 5 | 0.400 |
Why?
|
| Multivariate Analysis | 4 | 2021 | 561 | 0.400 |
Why?
|
| Antidepressive Agents | 2 | 2022 | 153 | 0.400 |
Why?
|
| Social Class | 3 | 2023 | 121 | 0.390 |
Why?
|
| Follow-Up Studies | 11 | 2024 | 1218 | 0.390 |
Why?
|
| Heart Failure | 1 | 2017 | 398 | 0.390 |
Why?
|
| Sleep Wake Disorders | 1 | 2012 | 37 | 0.380 |
Why?
|
| Inflammation | 1 | 2012 | 64 | 0.380 |
Why?
|
| Neoplasm Grading | 4 | 2017 | 49 | 0.380 |
Why?
|
| Mass Screening | 2 | 2009 | 667 | 0.380 |
Why?
|
| Prostate-Specific Antigen | 3 | 2016 | 75 | 0.380 |
Why?
|
| Prospective Studies | 11 | 2024 | 1287 | 0.370 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 108 | 0.370 |
Why?
|
| Registries | 7 | 2021 | 470 | 0.360 |
Why?
|
| Continental Population Groups | 2 | 2009 | 301 | 0.360 |
Why?
|
| Socioeconomic Factors | 3 | 2023 | 626 | 0.350 |
Why?
|
| Carcinoma, Ductal | 1 | 2010 | 4 | 0.340 |
Why?
|
| Body Mass Index | 3 | 2013 | 970 | 0.340 |
Why?
|
| Preventive Health Services | 1 | 2012 | 151 | 0.340 |
Why?
|
| Cross-Sectional Studies | 10 | 2012 | 1322 | 0.330 |
Why?
|
| Risk | 6 | 2020 | 517 | 0.330 |
Why?
|
| Electronic Health Records | 1 | 2015 | 694 | 0.330 |
Why?
|
| Comorbidity | 4 | 2023 | 590 | 0.320 |
Why?
|
| Case-Control Studies | 13 | 2015 | 1117 | 0.320 |
Why?
|
| Prostatectomy | 5 | 2016 | 75 | 0.320 |
Why?
|
| Incidence | 9 | 2015 | 1269 | 0.310 |
Why?
|
| Prostate | 2 | 2022 | 28 | 0.310 |
Why?
|
| Managed Care Programs | 1 | 2010 | 313 | 0.300 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 2017 | 10 | 0.290 |
Why?
|
| Water Supply | 3 | 2007 | 8 | 0.290 |
Why?
|
| Environmental Exposure | 4 | 2007 | 117 | 0.290 |
Why?
|
| Insurance Carriers | 1 | 2007 | 6 | 0.280 |
Why?
|
| Organizations, Nonprofit | 1 | 2007 | 11 | 0.280 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2010 | 324 | 0.280 |
Why?
|
| Keratosis | 2 | 2004 | 2 | 0.270 |
Why?
|
| Salvage Therapy | 2 | 2016 | 17 | 0.270 |
Why?
|
| Colorectal Neoplasms | 3 | 2010 | 616 | 0.260 |
Why?
|
| Treatment Outcome | 8 | 2024 | 1254 | 0.260 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 717 | 0.250 |
Why?
|
| Young Adult | 6 | 2022 | 2450 | 0.240 |
Why?
|
| Ethnic Groups | 2 | 2021 | 474 | 0.240 |
Why?
|
| HIV Infections | 3 | 2017 | 704 | 0.240 |
Why?
|
| Survival Rate | 4 | 2014 | 262 | 0.240 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2015 | 172 | 0.240 |
Why?
|
| Odds Ratio | 6 | 2017 | 670 | 0.230 |
Why?
|
| Receptor, ErbB-2 | 2 | 2016 | 47 | 0.230 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 304 | 0.230 |
Why?
|
| Mitomycin | 1 | 2024 | 4 | 0.230 |
Why?
|
| Isothiocyanates | 1 | 2024 | 8 | 0.230 |
Why?
|
| BCG Vaccine | 1 | 2024 | 7 | 0.230 |
Why?
|
| Logistic Models | 7 | 2013 | 918 | 0.220 |
Why?
|
| Ultrasonography | 2 | 2020 | 36 | 0.210 |
Why?
|
| Hyperpigmentation | 1 | 2003 | 1 | 0.210 |
Why?
|
| Early Detection of Cancer | 3 | 2020 | 513 | 0.210 |
Why?
|
| Colonoscopy | 1 | 2005 | 253 | 0.200 |
Why?
|
| Lower Urinary Tract Symptoms | 2 | 2013 | 13 | 0.200 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2022 | 32 | 0.200 |
Why?
|
| United States | 7 | 2015 | 3914 | 0.200 |
Why?
|
| Breast | 1 | 2022 | 85 | 0.190 |
Why?
|
| Hallucinogens | 1 | 2022 | 22 | 0.190 |
Why?
|
| Hip Fractures | 2 | 2015 | 70 | 0.190 |
Why?
|
| Arsenic Poisoning | 3 | 2007 | 3 | 0.190 |
Why?
|
| Feasibility Studies | 2 | 2020 | 111 | 0.180 |
Why?
|
| Sleep | 1 | 2021 | 58 | 0.180 |
Why?
|
| Depressive Disorder, Major | 1 | 2022 | 123 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2015 | 74 | 0.180 |
Why?
|
| Mammography | 3 | 2012 | 168 | 0.180 |
Why?
|
| Cannabis | 1 | 2022 | 81 | 0.180 |
Why?
|
| Erectile Dysfunction | 2 | 2011 | 24 | 0.170 |
Why?
|
| Watchful Waiting | 1 | 2020 | 18 | 0.170 |
Why?
|
| Wine | 2 | 2010 | 18 | 0.170 |
Why?
|
| Carcinoma in Situ | 2 | 2009 | 17 | 0.160 |
Why?
|
| Adolescent | 5 | 2017 | 3671 | 0.160 |
Why?
|
| Survival Analysis | 2 | 2017 | 216 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2020 | 215 | 0.160 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2009 | 53 | 0.160 |
Why?
|
| India | 7 | 2012 | 13 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 129 | 0.150 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 51 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 5 | 2024 | 80 | 0.150 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 58 | 0.150 |
Why?
|
| Vaccination | 1 | 2023 | 656 | 0.150 |
Why?
|
| Diabetes Mellitus | 2 | 2014 | 483 | 0.140 |
Why?
|
| Cell Cycle Proteins | 2 | 2015 | 6 | 0.140 |
Why?
|
| Apoptosis | 2 | 2015 | 10 | 0.140 |
Why?
|
| Exercise | 1 | 2022 | 496 | 0.140 |
Why?
|
| Leuprolide | 1 | 2017 | 2 | 0.140 |
Why?
|
| Goserelin | 1 | 2017 | 2 | 0.140 |
Why?
|
| Imidazolidines | 1 | 2017 | 2 | 0.140 |
Why?
|
| Flutamide | 1 | 2017 | 3 | 0.140 |
Why?
|
| Anilides | 1 | 2017 | 3 | 0.140 |
Why?
|
| Tosyl Compounds | 1 | 2017 | 3 | 0.140 |
Why?
|
| Nitriles | 1 | 2017 | 7 | 0.140 |
Why?
|
| Skin Diseases | 3 | 2005 | 10 | 0.140 |
Why?
|
| Hospitalization | 1 | 2023 | 805 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 60 | 0.140 |
Why?
|
| Clinical Laboratory Services | 1 | 2016 | 1 | 0.140 |
Why?
|
| Time Factors | 6 | 2013 | 1095 | 0.130 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2021 | 531 | 0.130 |
Why?
|
| Water Pollutants, Chemical | 2 | 2007 | 4 | 0.130 |
Why?
|
| Medical Records | 2 | 2008 | 97 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2016 | 84 | 0.130 |
Why?
|
| Disease Progression | 1 | 2017 | 266 | 0.130 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2015 | 15 | 0.130 |
Why?
|
| Immunohistochemistry | 4 | 2017 | 44 | 0.130 |
Why?
|
| Forecasting | 1 | 2016 | 74 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 4 | 0.130 |
Why?
|
| Macrophages | 1 | 2015 | 4 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 5 | 0.130 |
Why?
|
| Health Resources | 1 | 2015 | 36 | 0.120 |
Why?
|
| Smoking | 3 | 2022 | 483 | 0.120 |
Why?
|
| Nomograms | 1 | 2015 | 11 | 0.120 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 99 | 0.120 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 4 | 0.120 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 7 | 0.120 |
Why?
|
| SEER Program | 4 | 2017 | 92 | 0.120 |
Why?
|
| Mastectomy, Segmental | 2 | 2012 | 20 | 0.120 |
Why?
|
| European Continental Ancestry Group | 3 | 2012 | 523 | 0.120 |
Why?
|
| Prevalence | 6 | 2014 | 882 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 3 | 0.110 |
Why?
|
| Trans-Activators | 1 | 2013 | 8 | 0.110 |
Why?
|
| Health Behavior | 2 | 2015 | 360 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 65 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 355 | 0.100 |
Why?
|
| Men's Health | 2 | 2009 | 20 | 0.100 |
Why?
|
| Life Style | 2 | 2012 | 332 | 0.100 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 4 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 128 | 0.100 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2012 | 18 | 0.100 |
Why?
|
| Fractures, Bone | 1 | 2013 | 95 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 51 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 131 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 63 | 0.090 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2012 | 90 | 0.090 |
Why?
|
| Health Care Surveys | 1 | 2012 | 223 | 0.090 |
Why?
|
| Health Status | 2 | 2009 | 299 | 0.090 |
Why?
|
| Mammary Glands, Human | 1 | 2010 | 8 | 0.090 |
Why?
|
| Medical Audit | 1 | 2010 | 35 | 0.090 |
Why?
|
| Prostatitis | 1 | 2010 | 5 | 0.080 |
Why?
|
| Massachusetts | 1 | 2010 | 86 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2011 | 147 | 0.080 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2010 | 54 | 0.080 |
Why?
|
| Family Characteristics | 1 | 2009 | 56 | 0.080 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2009 | 86 | 0.080 |
Why?
|
| Educational Status | 1 | 2009 | 198 | 0.080 |
Why?
|
| Bias | 1 | 2009 | 103 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 3 | 0.080 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2008 | 7 | 0.080 |
Why?
|
| Quality of Life | 1 | 2012 | 521 | 0.080 |
Why?
|
| Body Height | 1 | 2008 | 62 | 0.070 |
Why?
|
| Child | 3 | 2022 | 2481 | 0.070 |
Why?
|
| Population Surveillance | 3 | 2016 | 265 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 212 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2020 | 1106 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2009 | 248 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 47 | 0.070 |
Why?
|
| Body Weight | 1 | 2008 | 226 | 0.070 |
Why?
|
| Fetal Development | 1 | 2007 | 14 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2007 | 30 | 0.070 |
Why?
|
| Age Factors | 3 | 2015 | 918 | 0.070 |
Why?
|
| Methionine | 1 | 2005 | 5 | 0.060 |
Why?
|
| Selenium | 1 | 2005 | 4 | 0.060 |
Why?
|
| Micronutrients | 1 | 2005 | 9 | 0.060 |
Why?
|
| beta Carotene | 1 | 2005 | 17 | 0.060 |
Why?
|
| Water | 1 | 2005 | 2 | 0.060 |
Why?
|
| Respiration Disorders | 1 | 2005 | 5 | 0.060 |
Why?
|
| Bronchiectasis | 1 | 2005 | 7 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 755 | 0.060 |
Why?
|
| Surveys and Questionnaires | 4 | 2011 | 1322 | 0.060 |
Why?
|
| Automation | 1 | 2005 | 24 | 0.060 |
Why?
|
| Nutrition Disorders | 1 | 2004 | 1 | 0.060 |
Why?
|
| Skin Pigmentation | 1 | 2004 | 6 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2024 | 7 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2024 | 16 | 0.060 |
Why?
|
| Biopsy | 2 | 2017 | 75 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2015 | 6 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 29 | 0.050 |
Why?
|
| Rural Population | 1 | 2003 | 52 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 9 | 0.050 |
Why?
|
| Telomere | 1 | 2022 | 19 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 100 | 0.050 |
Why?
|
| Diet | 1 | 2024 | 367 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2013 | 19 | 0.050 |
Why?
|
| Ovary | 1 | 2020 | 4 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2020 | 5 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 6 | 0.040 |
Why?
|
| Heterozygote | 1 | 2020 | 26 | 0.040 |
Why?
|
| Mutation | 1 | 2020 | 131 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 23 | 0.040 |
Why?
|
| ROC Curve | 1 | 2017 | 77 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 15 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 181 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 312 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2009 | 448 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 3 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2015 | 28 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2015 | 5 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 6 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 371 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 14 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2015 | 160 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2015 | 3 | 0.030 |
Why?
|
| Interferon Regulatory Factors | 1 | 2015 | 3 | 0.030 |
Why?
|
| Protein Kinase C beta | 1 | 2015 | 3 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2015 | 4 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 5 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2015 | 8 | 0.030 |
Why?
|
| Women's Health | 1 | 2015 | 199 | 0.030 |
Why?
|
| Postmenopause | 1 | 2015 | 243 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2014 | 6 | 0.030 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2014 | 8 | 0.030 |
Why?
|
| Michigan | 1 | 2014 | 26 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 13 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 234 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 118 | 0.030 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2013 | 3 | 0.030 |
Why?
|
| Cause of Death | 1 | 2014 | 181 | 0.030 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Ki-1 Antigen | 1 | 2012 | 3 | 0.030 |
Why?
|
| B7-1 Antigen | 1 | 2012 | 3 | 0.030 |
Why?
|
| LIM Domain Proteins | 1 | 2012 | 3 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 6 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2012 | 13 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 15 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2012 | 6 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2012 | 11 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 32 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 190 | 0.020 |
Why?
|
| Asian Americans | 1 | 2011 | 175 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 30 | 0.020 |
Why?
|
| Acculturation | 1 | 2009 | 20 | 0.020 |
Why?
|
| Mastectomy | 1 | 2009 | 36 | 0.020 |
Why?
|
| Hispanic Americans | 1 | 2011 | 397 | 0.020 |
Why?
|
| Language | 1 | 2009 | 52 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 146 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 75 | 0.020 |
Why?
|
| Dutasteride | 1 | 2008 | 1 | 0.020 |
Why?
|
| Azasteroids | 1 | 2008 | 1 | 0.020 |
Why?
|
| Finasteride | 1 | 2008 | 1 | 0.020 |
Why?
|
| African Continental Ancestry Group | 1 | 2009 | 162 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2008 | 9 | 0.020 |
Why?
|
| Propensity Score | 1 | 2009 | 85 | 0.020 |
Why?
|
| Recurrence | 1 | 2009 | 189 | 0.020 |
Why?
|
| African Americans | 1 | 2011 | 465 | 0.020 |
Why?
|
| Prostatic Hyperplasia | 1 | 2008 | 24 | 0.020 |
Why?
|
| Health Services Research | 1 | 2009 | 213 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2008 | 50 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 237 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 246 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2007 | 4 | 0.020 |
Why?
|
| Exanthema | 1 | 2007 | 7 | 0.020 |
Why?
|
| Epidemiological Monitoring | 1 | 2007 | 25 | 0.020 |
Why?
|
| Environmental Monitoring | 1 | 2007 | 26 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 49 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2005 | 32 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 154 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2008 | 361 | 0.010 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2007 | 167 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2004 | 31 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 211 | 0.010 |
Why?
|
| Health Surveys | 1 | 2004 | 260 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2007 | 1417 | 0.010 |
Why?
|
| Pregnancy | 1 | 2007 | 1535 | 0.010 |
Why?
|